Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
This randomized phase III trial studies how well hypofractionated radiation therapy works in preventing recurrence in patients with stage IIa-IIIa cancer who have undergone mastectomy. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells that remain after surgery and have fewer side effects.
- Ductal Breast Carcinoma
- Invasive Breast Carcinoma
- Lobular Breast Carcinoma
- Medullary Breast Carcinoma
- Stage II Breast Cancer
- Stage IIA Breast Cancer
- Stage IIB Breast Cancer
- Stage IIIA Breast Cancer
- Tubular Breast Carcinoma
- Eligible Ages
- Over 18 Years
- Eligible Genders
- Accepts Healthy Volunteers
- Histologically confirmed invasive carcinoma of the breast of any of the following
histologies (ductal, lobular, mammary, medullary, or tubular); patients with
metaplastic breast cancer are not eligible
- Patients will be staged according to the TNM staging system
- For patients not receiving neoadjuvant chemotherapy, pathologic staging must be
T0N1-2a, T1N1-2a, T2N1-2a, T3N0-2a, and all M0 status
- For patients receiving neoadjuvant chemotherapy, clinical pre-chemo staging and
post mastectomy pathological staging is required for all patients; patients who
have received neoadjuvant chemotherapy and are pathologically cT0-2 and N0 are
only eligible if biopsy-proven clinically N1 or N2 disease is documented prior to
the start of neoadjuvant chemotherapy; cT3N0 patients or ypT3N0 patients who
receive neoadjuvant chemotherapy may be eligible based on clinical or
pathological T stage, and do not require pathologically positive lymph nodes
- Note: Higher of the clinical or pathological T and N stage are used for final
staging, if receiving neoadjuvant chemotherapy; all patients with clinical,
radiographic or pathological T4, N3 or involved internal mammary disease (N1b,
N1c, and N2b) are not eligible
- No prior therapeutic radiation therapy to the chest, neck or axilla; prior radioactive
oral iodine is permitted
- No prior history of ipsilateral breast cancer (invasive disease or ductal breast
carcinoma in situ [DCIS]); lobular carcinoma in situ (LCIS) and benign breast disease
- No history of prior or concurrent contralateral invasive breast cancer; benign breast
disease, LCIS or DCIS of contralateral breast is allowed
- No active collagen vascular diseases, such as: systemic lupus erythematous,
scleroderma, or dermatomyositis
- Negative inked histologic margins from mastectomy pathology (no invasive cells at
- No significant post mastectomy complications in the ipsilateral breast requiring an
unplanned re-operation or admission for intravenous (IV) antibiotics; re-operation for
margins evaluation, nodal completion and routine reconstruction is acceptable
- Radiation oncologist intends to treat all target volumes and respect all normal
tissues in accordance with the dosimetric constraints described (simulation before
- Radiation oncologist is planning to treat regional lymph nodes including internal
mammary nodes and meet acceptable protocol dosimetric requirements
- Radiation oncologist is NOT planning to utilize a chest wall/scar boost
- Patient must have undergone immediate reconstruction at the time of mastectomy or be
planning to undergo reconstruction within 18 months after radiation
- If a tissue expander is utilized it needs to be a fluid filled expander, NO air
expander (unless completely deflated) during radiation therapy
- For patients with diabetes, hemoglobin A1C test must have been performed =< 90 days
prior to registration
- No co-existing medical conditions with life expectancy < 5 years
- No other malignancy within 5 years of registration with the exception of basal cell or
squamous cell carcinoma of the skin treated with local resection only or carcinoma in
situ of the cervix
- Negative serum or urine beta-human chorionic gonadotropin (HCG) in women of
child-bearing potential =< 7 days prior to registration; a female of childbearing
potential is a sexually mature female who has not undergone a hysterectomy or
bilateral oophorectomy and has not been naturally postmenopausal for at least 12
- Women of child-bearing potential must agree to utilize a form of birth control or
agree to undergo sexual abstinence during radiation therapy
- Eastern Cooperative Oncology Group (ECOG) (Zubrod) performance status 0-1
- Patients must be able to read and comprehend English, in order to be able to complete
study questionnaires; however, patients participating through Canadian Cancer Trials
Group (CCTG) institutions who can read and comprehend French are eligible
- Phase 3
- Study Type
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Supportive Care
- None (Open Label)
Group I (radiation therapy)
|Patients undergo radiation therapy daily on Monday-Friday for 5-6 weeks.||
Group II (hypofractionated radiation therapy)
|Patients undergo hypofractionated radiation therapy daily on Monday-Friday for 3-4 weeks.||
- Alliance for Clinical Trials in Oncology
Study ContactMatthew Poppe, MD
I. To evaluate whether the reconstruction complication rate at 24 months post radiation is non-inferior with hypofractionation.
I. To evaluate the incidence of acute and late radiation complications, based on Common Terminology Criteria for Adverse Events (CTCAE) 4.0 toxicity.
II. To evaluate the local and local regional recurrence rate. III. To compare reconstruction complication rates based on reconstruction method (autologous +/- implant versus [vs] implant only) and timing of reconstruction received (immediate vs. intent for delayed).
I. To evaluate reconstructed breast photographic cosmetic scores with hypofractionated radiation compared to standard fractionation 24 months after radiation.
II. To evaluate reconstructed breast photographic cosmetic scores 24 months after radiation based on the method and timing of reconstruction received.
III. To estimate the incidence of arm lymphedema by treatment arm. IV. To compare physical well-being, psychosocial well-being, sexual well-being, satisfaction with breast/nipples/abdomen, and satisfaction with overall outcome between the treatment arms at 24 months after radiation.
V. To estimate patient satisfaction with trial participation by treatment arm as measured by the Was It Worth It Questionnaire at 24 months after radiation.
VI. To compare the direct and indirect patient costs for radiation therapy by treatment arm.
VII. To compare patient reported total health care service utilization 12 months after the completion of radiation.
VIII. To compare the economic impact of treatment. IX. To analyze polymorphisms in MDM2 and in genes including TP53, ATM, TGFB1, IL4, IL6, and IL10 and determine correlations with a higher likelihood of adverse radiation reactions (radiation sensitivity) and with toxicities.
X. To analyze polymorphisms in MDM2 and in genes including TP53, ATM, TGFB1, IL4, IL6, and IL10 to determine correlations with secondary endpoints such as local-regional control.
OUTLINE: Patients are randomized to 1 of 2 groups.
GROUP I: Patients undergo radiation therapy daily on Monday-Friday for 5-6 weeks.
GROUP II: Patients undergo hypofractionated radiation therapy daily on Monday-Friday for 3-4 weeks.
After completion of study, patients are followed up for 5 years.